480 related articles for article (PubMed ID: 31253115)
1. Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres.
Riccardi N; Alagna R; Saderi L; Ferrarese M; Castellotti P; Mazzola E; De Lorenzo S; Viggiani P; Udwadia Z; Besozzi G; Cirillo D; Sotgiu G; Codecasa L;
BMC Infect Dis; 2019 Jun; 19(1):564. PubMed ID: 31253115
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology and treatment outcome of MDR and pre-XDR TB in international migrants at two reference centers in the North of Italy: a cross-sectional study coordinated by Stop TB Italia Onlus.
Riccardi N; Pontarelli A; Alagna R; Saderi L; Ferrarese M; Castellotti P; Viggiani P; Cirillo D; Besozzi G; Sotgiu G; Codecasa L;
Public Health; 2020 Mar; 180():17-21. PubMed ID: 31837610
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic strategies and outcomes of MDR and pre-XDR-TB in Italy: a nationwide study.
Riccardi N; Saderi L; Borroni E; Tagliani E; Cirillo DM; Marchese V; Matteelli A; Piana A; Castellotti P; Ferrarese M; Gualano G; Palmieri F; Girardi E; Codecasa L; Sotgiu G
Int J Tuberc Lung Dis; 2021 May; 25(5):395-399. PubMed ID: 33977908
[No Abstract] [Full Text] [Related]
4. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China.
Alene KA; Yi H; Viney K; McBryde ES; Yang K; Bai L; Gray DJ; Clements ACA; Xu Z
BMC Infect Dis; 2017 Aug; 17(1):573. PubMed ID: 28814276
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.
Borisov SE; Dheda K; Enwerem M; Romero Leyet R; D'Ambrosio L; Centis R; Sotgiu G; Tiberi S; Alffenaar JW; Maryandyshev A; Belilovski E; Ganatra S; Skrahina A; Akkerman O; Aleksa A; Amale R; Artsukevich J; Bruchfeld J; Caminero JA; Carpena Martinez I; Codecasa L; Dalcolmo M; Denholm J; Douglas P; Duarte R; Esmail A; Fadul M; Filippov A; Davies Forsman L; Gaga M; Garcia-Fuertes JA; García-García JM; Gualano G; Jonsson J; Kunst H; Lau JS; Lazaro Mastrapa B; Teran Troya JL; Manga S; Manika K; González Montaner P; Mullerpattan J; Oelofse S; Ortelli M; Palmero DJ; Palmieri F; Papalia A; Papavasileiou A; Payen MC; Pontali E; Robalo Cordeiro C; Saderi L; Sadutshang TD; Sanukevich T; Solodovnikova V; Spanevello A; Topgyal S; Toscanini F; Tramontana AR; Udwadia ZF; Viggiani P; White V; Zumla A; Migliori GB
Eur Respir J; 2017 May; 49(5):. PubMed ID: 28529205
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
Tiberi S; Payen MC; Sotgiu G; D'Ambrosio L; Alarcon Guizado V; Alffenaar JW; Abdo Arbex M; Caminero JA; Centis R; De Lorenzo S; Gaga M; Gualano G; Roby Arias AJ; Scardigli A; Skrahina A; Solovic I; Sulis G; Tadolini M; Akkerman OW; Alarcon Arrascue E; Aleska A; Avchinko V; Bonini EH; Chong Marín FA; Collahuazo López L; de Vries G; Dore S; Kunst H; Matteelli A; Moschos C; Palmieri F; Papavasileiou A; Spanevello A; Vargas Vasquez D; Viggiani P; White V; Zumla A; Migliori GB
Eur Respir J; 2016 Apr; 47(4):1235-43. PubMed ID: 26965290
[TBL] [Abstract][Full Text] [Related]
7. Epidemiological trends and outcomes of extensively drug-resistant tuberculosis in Shandong, China.
He XC; Tao NN; Liu Y; Zhang XX; Li HC
BMC Infect Dis; 2017 Aug; 17(1):555. PubMed ID: 28793873
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of rapid susceptibility testing against second-line drugs for tuberculosis.
Dowdy DW; van't Hoog A; Shah M; Cobelens F
Int J Tuberc Lung Dis; 2014 Jun; 18(6):647-54. PubMed ID: 24903933
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis.
Kim DH; Kim HJ; Park SK; Kong SJ; Kim YS; Kim TH; Kim EK; Lee KM; Lee SS; Park JS; Koh WJ; Lee CH; Shim TS
Am J Respir Crit Care Med; 2010 Jul; 182(1):113-9. PubMed ID: 20224066
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of pulmonary MDR-TB: impacts of fluoroquinolone resistance and linezolid treatment.
Jeong BH; Jeon K; Park HY; Kwon OJ; Lee KS; Kim HK; Choi YS; Kim J; Huh HJ; Lee NY; Koh WJ
J Antimicrob Chemother; 2015 Nov; 70(11):3127-33. PubMed ID: 26203184
[TBL] [Abstract][Full Text] [Related]
11. Survival of patients with multidrug-resistant TB in Eastern Europe: what makes a difference?
Balabanova Y; Ignatyeva O; Fiebig L; Riekstina V; Danilovits M; Jaama K; Davidaviciene E; Radiulyte B; Popa CM; Nikolayevskyy V; Drobniewski F
Thorax; 2016 Sep; 71(9):854-61. PubMed ID: 27012887
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of mutations associated with resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients from high prevalence tuberculosis city in Morocco.
Oudghiri A; Karimi H; Chetioui F; Zakham F; Bourkadi JE; Elmessaoudi MD; Laglaoui A; Chaoui I; El Mzibri M
BMC Infect Dis; 2018 Feb; 18(1):98. PubMed ID: 29486710
[TBL] [Abstract][Full Text] [Related]
13. Early detection of multidrug- and pre-extensively drug-resistant tuberculosis from smear-positive sputum by direct sequencing.
Chen J; Peng P; Du Y; Ren Y; Chen L; Rao Y; Wang W
BMC Infect Dis; 2017 Apr; 17(1):300. PubMed ID: 28438132
[TBL] [Abstract][Full Text] [Related]
14. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
[TBL] [Abstract][Full Text] [Related]
15. Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis.
Blöndal K; Viiklepp P; Guðmundsson LJ; Altraja A
Int J Tuberc Lung Dis; 2012 Sep; 16(9):1228-33. PubMed ID: 22748131
[TBL] [Abstract][Full Text] [Related]
16. The burden of pre-extensively and extensively drug-resistant tuberculosis among MDR-TB patients in the Amhara region, Ethiopia.
Shibabaw A; Gelaw B; Gebreyes W; Robinson R; Wang SH; Tessema B
PLoS One; 2020; 15(2):e0229040. PubMed ID: 32053661
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients in Viet Nam, 2011.
Nguyen HB; Nguyen NV; Tran HT; Nguyen HV; Bui QT
Western Pac Surveill Response J; 2016; 7(2):35-40. PubMed ID: 27508089
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: a retrospective hospital-based study.
Sharma SK; George N; Kadhiravan T; Saha PK; Mishra HK; Hanif M
Indian J Med Res; 2009 Oct; 130(4):392-5. PubMed ID: 19942741
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and treatment outcome of extensively drug-resistant tuberculosis plus additional drug resistance from the National Clinical Center for Tuberculosis in China: A five-year review.
Pang Y; Lu J; Huo F; Ma Y; Zhao L; Li Y; Liang Q; Chu N; Gao M; Huang H
J Infect; 2017 Nov; 75(5):433-440. PubMed ID: 28804028
[TBL] [Abstract][Full Text] [Related]
20. Treatment outcomes of pre- and extensively drug-resistant tuberculosis in Johannesburg, South Africa.
Nkurunziza J; Karstaedt AS; Louw R; Padanilam X
Int J Tuberc Lung Dis; 2018 Dec; 22(12):1469-1474. PubMed ID: 30606319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
